EP 3302464 A4 20190123 - USE OF CANNABINOIDS IN THE TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN
Title (en)
USE OF CANNABINOIDS IN THE TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN
Title (de)
VERWENDUNG VON CANNABINOIDEN ZUR BEHANDLUNG VON AUGENENTZÜNDUNGEN UND/ODER SCHMERZEN
Title (fr)
UTILISATION DE CANNABINOÏDES DANS LE TRAITEMENT DE L'INFLAMMATION ET/OU DE LA DOULEUR OCULAIRE
Publication
Application
Priority
- US 201514722991 A 20150527
- CA 2016050603 W 20160527
Abstract (en)
[origin: WO2016187722A1] Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a CB2 agonist, a CB2 partial agonist, or a CB2 positive allosteric modulator. In preferred embodiments, the CB2 target agent is dimethyl heptyl cannabidiol (CBD-DMH), while the cannabimimetic agent is selected from the group consisting of Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinol, (Δ9-THC), CP55940, and WIN55212-2.
IPC 8 full level
A61K 31/352 (2006.01); A61K 31/05 (2006.01); A61K 45/06 (2006.01); A61P 25/02 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); C07C 39/23 (2006.01); C07D 311/80 (2006.01)
CPC (source: EP)
A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 45/06 (2013.01); A61P 25/02 (2017.12); A61P 29/00 (2017.12)
Citation (search report)
- [XPI] WO 2015074137 A1 20150528 - LYNCH MARY [CA], et al
- [XI] WO 2014100231 A1 20140626 - KOTZKER CONSULTING LLC [US]
- [I] US 2009247619 A1 20091001 - STINCHCOMB AUDRA L [US], et al
- See references of WO 2016187722A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2016187722 A1 20161201; EP 3302464 A1 20180411; EP 3302464 A4 20190123
DOCDB simple family (application)
CA 2016050603 W 20160527; EP 16799004 A 20160527